metricas
covid
Annals of Hepatology EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS A...
Journal Information

Statistics

Follow this link to access the full text of the article

#129
EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL
Alejandra M. Villamil1, Ziad Younes2, Christopher L. Bowlus3, John M. Vierling4, Adam Vasura5, Andrea Galli6, Mordechai Rabinovitz7, Frederik Nevens8, Susheela Carroll9, Ke Yang9, Daria B. Crittenden9, Charles A. McWherter10, Eric J. Lawitz11
1 The Liver Autoimmunity Unit. Hospital Italiano de Buenos Aires, Argentina.
2 Gastro One, USA.
3 Division of Gastroenterology and Hepatology. University of California Davis School of Medicine, USA.
4 Baylor College of Medicine, USA.
5 Department of Gastroenterology. University Hospital Ostrava, Czech Republic.
6 Azienda Ospedaliero Universitaria Careggi Gastroenterologia Clinica, Italia.
7 University of Pittsburgh, USA.
8 Hepatology and Liver Transplantation. University Hospitals KU Leuven and Center of European Reference Network (ERN) RARE-LIVER, Belgium.
9 Gilead Sciences, Inc, USA.
10 CymaBay Therapeutics, Inc, USA.
11 Texas Liver Institute. University of Texas Health San Antonio, USA.
Ver más
Read
249
Times
was read the article
64
Total PDF
185
Total HTML
Share statistics
Article information
ISSN: 16652681
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 23 0 23
2025 11 110 33 143
2025 10 47 26 73
2025 9 5 5 10

Follow this link to access the full text of the article